Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 6, 2020

View Archived Issues

From African genomes, big insights with small sample size

Commercial antibodies underwhelm for studies of PP2A

TUSC2 as a novel therapeutic target in thyroid carcinoma

Gedeon Richter patents alpha-7 nicotinic receptor positive allosteric modulators

New compounds for RNA virus infections described by CNRS and others

Rodin Therapeutics identifies new HDAC inhibitors

New Trk-A, Trk-B and Trk-C inhibitors discovered at BenevolentAI Bio

Pfizer identifies new monoglyceride lipase inhibitors

FDA clears IND application for BXCL-501 for the treatment of opioid withdrawal symptoms

Lamivudine shows promising safety and activity in p53 mutant mCRC

Phase Ib results for ficlatuzumab plus gemcitabine and nab-paclitaxel in PDAC

Interim phase I/II data for LOAd-703 plus nab-paclitaxel/gemcitabine in PDAC

Reducing stem cell senescence protects against aging

Interim phase I data on Arrowhead's ARO-APOC3 and ARO-ANG3 show improvements in lipid parameters

Phase IIb study of SAR-442168 in relapsing MS meets primary endpoint

Tonix stops enrollment in phase III PTSD study of Tonmya for futility

Antitumor activity seen with pembrolizumab in advanced anal squamous cell carcinoma trial

BiondVax reports preliminary phase II data on M-001 universal influenza vaccine candidate

Arthrosi begins phase IIa study of AR-882 for gout

Atreca and Merck & Co. collaborate to identify antibody targets in oncology

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...